Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy

Leukemia. 2020 Nov;34(11):3088-3090. doi: 10.1038/s41375-020-0860-7. Epub 2020 May 12.

Authors

Atsushi Suzuki^#¹, Satoshi Kakugawa^#², Masafumi Miyoshi^#², Mitsuo Hori³, Kenshi Suzuki⁴, Yusuke Furukawa⁵, Kensuke Ohta⁶

Affiliations

¹ Bristol-Myers Squibb K.K., Shinjuku, Tokyo, Japan. atsushi.suzuki@bms.com.
² Bristol-Myers Squibb K.K., Shinjuku, Tokyo, Japan.
³ Department of Hematology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
⁴ Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
⁵ Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
⁶ Hematology Ohta Clinic, Shinsaibashi, Osaka, Japan.

^# Contributed equally.

PMID: 32398792
DOI: 10.1038/s41375-020-0860-7

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / drug effects*
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Biomarkers, Tumor*
Humans
Multiple Myeloma / blood*
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Prognosis
Signaling Lymphocytic Activation Molecule Family / blood*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Biomarkers, Tumor
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family
elotuzumab

Associated data

ClinicalTrials.gov/NCT02272803